Publication: Multimodal Hazard Rate for Relapse in Breast Cancer: Quality of Data and Calibration of Computer Simulation
Open/View Files
Date
2014
Authors
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI AG
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Retsky, Michael, and Romano Demicheli. 2014. “Multimodal Hazard Rate for Relapse in Breast Cancer: Quality of Data and Calibration of Computer Simulation.” Cancers 6 (4) (November 27): 2343–2355. doi:10.3390/cancers6042343.
Research Data
Abstract
Much has occurred since our 2010 report in Cancers. In the past few years we published several extensive reviews of our research so a brief review is all that will be provided here. We proposed in the earlier reports that most relapses in breast cancer occur within 5 years of surgery and seem to be associated with some unspecified manner of surgery-induced metastatic initiation. These events can be identified in relapse data and are correlated with clinical data. In the last few years an unexpected mechanism has become apparent. Retrospective analysis of relapse events by a Brussels anesthesiology group reported that a perioperative NSAID analgesic seems to reduce early relapses five-fold. We then proposed that primary surgery produces a transient period of systemic inflammation. This has now been identified by inflammatory markers in serum post mastectomy. That could explain the early relapses. It is possible that an inexpensive and non-toxic NSAID can reduce breast cancer relapses significantly. We want to take this opportunity to discuss database quality issues and our relapse hazard data in some detail. We also present a demonstration that the computer simulation can be calibrated with Adjuvant-on-line, an often used clinical tool for prognosis in breast cancer.
Description
Other Available Sources
Keywords
breast cancer, bimodal and multimodal relapse patterns, database quality, early relapses, surgery, perioperative NSAID, transient systemic inflammation
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service